Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

Clinical Infectious Diseases

Volumn 37, Issue 12, 2003, Pages 1668-1677

  Durbin, Anna P ^a,b   Karron, Ruth A ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; LIVE VACCINE; PARAINFLUENZA VACCINE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS GLYCOPROTEIN;

ARTICLE; CLINICAL TRIAL; DRUG RESEARCH; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINE PRODUCTION;

ADULT; CHILD; HUMANS; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 0347479195     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379775     Document Type: Article

References (119)

1. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology. 4th ed. Vol 1. Philadelphia: Lippincott Williams & Wilkins, 2001: 1443-85.
2. Hall CB. Prospects for a respiratory syncytial virus vaccine. Science 1994; 265:1393-4.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-6.
4. Fouillard L, Mouthon L, Laporte JP, et al. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9: 97-100.
5. Falsey AR. Respiratory syncytial virus infection in older persons. Vaccine 1998; 16:1775-8.
6. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992; 40:115-9.
7. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84.
8. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999; 179:25-30.
9. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development: prospects for immunizing against respiratory syncytial virus. In: Nichols EK, ed. New vaccine development: establishing priorities. Vol 1. Washington, DC: National Academy of Sciences Press, 1985:397-409.
10. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 1997; 175:807-13.
11. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498-505.
12. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984; 150:851-7.
13. Wright PF. Parainfluenza viruses. In: Belshe RB, ed. Textbook of human virology. 2nd ed. Littleton, MA: PSG Publishing, 1984:299-307.
14. Karron RA, O'Brien KL, Froehlich JL, Brown VA. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. J Infect Dis 1993; 167:1441-5.
15. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization: respiratory syncytial and parainfluenza viruses. J Infect Dis 1990; 161:402-6.
16. Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology. 4th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001:1341-79.
17. Madhi SA, Ramasamy N, Petersen K, Madhi A, Klugman KP. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1. Eur J Clin Microbiol Infect Dis 2002; 21:499-505.
18. Cortez KJ, Erdman DD, Peret TC, et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001; 184:1093-7.
19. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
20. Parrott RH, Vargosko A, Luckey A, Kim HW, Cumming C, Chanock RM. Clinical features of infection with hemadsorption viruses. N Engl J Med 1959; 260:731-8.
21. Parrott RH, Vargosko A, Kim HW, Bell JA, Chanock RM. Acute respiratory diseases of viral etiology. Am J Public Health 1962; 52: 907-17.
22. Mufson MA, Levine HD, Wasil RE, Mocega-Gonzalez HE, Krause HE. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am J Epidemiol 1973; 98:88-95.
23. Spence L, Barratt N. Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients. Am J Epidemiol 1968; 88:257-66.
24. Smith CB, Purcell RH, Bellanti JA, Chanock RM. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966; 275: 1145-52.
25. Tremonti LP, Lin JS, Jackson GG. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol 1968; 101:572-7.
26. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
27. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75:10730-7.
28. Tao T, Davoodi F, Cho CJ, et al. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin- neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 2000; 18:1359-66.
29. Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 1999; 17:1100-8.
30. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002; 110:21-7.
31. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
32. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
33. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48.
34. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-63.
35. Murphy BR, Prince GA, Walsh EE, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986; 24:197-202.
36. Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976; 10:75-8.
37. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-40.
38. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996; 70:2852-60.
39. + T cells. J Virol 1992; 66:7444-51.
40. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 1997; 27:3341-9.
41. Tang YW, Neuzil KM, Fischer JE, Robinson FW, Parker RA, Graham BS. Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine 1997; 15:597-602.
42. Neuzil KM, Johnson JE, Tang YW, et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997; 15:525-32.
43. Crowe JE, Collins PL, Chanock RM, Murphy BR. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. New York: Marcel Dekker, 1997:711-25.
44. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196: 859-65.
45. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994; 32:13-36.
46. Tang YW, Graham BS. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogeniciry. J Infect Dis 1995; 172:734-8.
47. Clements ML, Makhene MK, Karron RA, et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center. J Infect Dis 1996; 173:44-51.
48. Karron RA, Steinhoff MC, Subbarao EK, et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995; 14:10-6.
49. Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996; 15:650-4.
50. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
51. Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003; 22:394-405.
52. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985; 3:355-69.
53. Chanock RM, Murphy BR. Past efforts to develop safe and effective RSV vaccines. In: Meignier B, ed. Animal models of respiratory syncytial virus infections. Lyon, France: Merieux Foundation Publication, 1991:35-42.
54. McIntosh K, Arbeter AM, Stahl MK, Orr IA, Hodes DS, Ellis EF. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr Res 1974; 8:689-96.
55. Kim HW, Arrobio JO, Brandt CD, et al. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 1973; 52:56-63.
56. Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 1976; 88:931-6.
57. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13:847-55.
58. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicityand protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994; 12:783-90.
59. Crowe JE Jr, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12: 691-9.
60. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11:1395-404.
61. Karron RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428-36.
62. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995; 92:11563-7.
63. Collins PL, Whitehead SS, Bukreyev A, et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999; 54:423-51.
64. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999; 17:1416-24.
65. Whitehead SS, Firestone CY, Collins PL, Murphy BR. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998; 247:232-9.
66. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/ 1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999; 73:871-7.
67. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000; 273: 210-8.
68. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997; 71: 8973-82.
69. Whitehead SS, Bukreyev A, Teng MN, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999; 73:3438-42.
70. Karron RA, Wright PF, Belshe RB, Randolph VB, Whitehead SS, Murphy BR. Evaluation of live rRSV A2 vaccines in infants and children [abstract 5.2]. In: RSV after 45 years. Segovia, Spain: Instituto de Salud Carlos, Ministerio de Sanidad y Consumo, 2001:32.
71. Bukreyev A, Camargo E, Collins PL. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol 1996; 70:6634-41.
72. Whitehead SS, Hill MG, Firestone CY, et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 1999; 73:9773-80.
73. Jin H, Clarke D, Zhou HZ, et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 1998; 251:206-14.
74. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996; 14:1214-8.
75. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997; 15:1130-2.
76. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993; 168:1024-9.
77. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994; 13:792-8.
78. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993; 167:191-5.
79. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996; 15:23-31.
80. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998; 177:467-9.
81. Munoz FM, Piedra PA, Maccato M, Kozinetz C, Glezen WP. Respiratory syncytial virus purified fusion protein-2 (RSV-PFP-2) vaccine in pregnancy [abstract]. In: RSV After 45 Years. Segovia, Spain: Instituto de Salud Carlos, Ministerio de Sanidad y Consumo, 2001:45.
82. Sales V, Goldwater R, Warren JT, Yi Q, Caudrelier P. Safety and immunogenicity of a respiratory syncytial virus subtype A vaccine in adults - two phase I studies [abstract]. In: Program and abstracts of the 4th International Symposium on Respiratory Viral Infections. Curacao, Netherlands Antilles, 2001:12.
83. + T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J Virol 2000; 74:3455-63.
84. Plotnicky-Gilquin H, Huss T, Aubry JP, et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 1999; 258:128-40.
85. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997; 230:155-66.
86. Power UF, Nguyen TN, Rietveld E, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001; 184:1456-60.
87. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000; 18:1763-72.
88. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001; 20:954-60.
89. Piedra PA, Grace S, Jewell A, et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 1998; 17:217-24.
90. Brandt C, Power UF, Plotnicky-Gilquin H, et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 1997; 176:884-91.
91. Plotnicky-Gilquin H, Goetsch L, Huss T, et al. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 1999; 73:5637-45.
92. Power UF, Plotnicky-Gilquin H, Goetsch L, et al. Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein. Vaccine 2001; 19:2345-51.
93. Norrby E, Mufson MA, Alexander H, Houghten RA, Lerner RA. Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus. Proc Natl Acad Sci USA 1987; 84:6572-6.
94. Belshe RB, Hissom FK. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 1982; 10: 235-42.
95. Skiadopoulos MH, Durbin AP, Tatem JM, et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998; 72:1762-8.
96. Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999; 73: 1374-81.
97. Coelingh KL, Winter CC, Murphy BR, et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986; 60:90-6.
98. Bailly JE, McAuliffe JM, Skiadopoulos MH, Collins PL, Murphy BR. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates. Virus Genes 2000; 20:173-82.
99. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991; 29: 1175-82.
100. Karron RA, Wright PF, Hall SL, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995; 171: 1107-14.
101. Karron RA, Wright PF, Newman FK, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995; 172:1445-50.
102. Hurwitz JL, Soike KF, Sangster MY, et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 1997; 15:533-40.
103. Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 2002; 297:153-60.
104. Durbin AP, Hall SL, Siew JW, Whitehead SS, Collins PL, Murphy BR. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 1997; 235:323-32.
105. Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 2000; 74:11626-35.
106. Durbin AP, McAuliffe JM, Collins PL, Murphy BR. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999; 261: 319-30.
107. Bailly JE, McAuliffe JM, Durbin AP, Elkins WR, Collins PL, Murphy BR. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol 2000; 74:3188-95.
108. Skiadopoulos MH, Surman SR, St Claire M, Elkins WR, Collins PL, Murphy BR. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 1999; 260:125-35.
109. Schmidt AC, McAuliffe JM, Huang A, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000; 74:8922-9.
110. Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins PL, Murphy BR. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 1998; 72:2955-61.
111. Tao T, Skiadopoulos MH, Davoodi F, Riggs JM, Collins PL, Murphy BR. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J Virol 2000; 74:6448-58.
112. Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Vaccine 2001; 19:3620-31.
113. Newman JT, Surman SR, Riggs JM, et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 2002; 24:77-92.
114. Skiadopoulos MH, Vogel L, Riggs JM, Surman SR, Collins PL, Murphy BR. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 2003; 77:270-9.
115. Durbin AP, Skiadopoulos MH, McAuliffe JM, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 2000; 74:6821-31.
116. Skiadopoulos MH, Surman SR, Riggs JM, Collins PL, Murphy BR. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J Virol 2001; 75:10498-504.
117. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/ human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 2001; 75:4594-603.
118. Schmidt AC, Wenzke DR, McAuliffe JM, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 2002; 76:1089-99.
119. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-24.